



2023 Sustainability Highlights

Conference call for investors and analysts

March 2024



Forward-looking statements

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: this document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group's control, include, among other things: the risk of failure or delay in delivery of pipeline or launch of new medicines; the risk of failure to meet regulatory or ethical requirements for medicine development or approval; the risk of failure to obtain, defend and enforce effective IP protection and IP challenges by third parties; the impact of competitive pressures including expiry or loss of IP rights, and generic competition; the impact of price controls and reductions; the impact of economic, regulatory and political pressures; the impact of uncertainty and volatility in relation to the UK's exit from the EU; the risk of failures or delays in the quality or execution of the Group's commercial strategies; the risk of failure to maintain supply of compliant, quality medicines; the risk of illegal trade in the Group's medicines; the impact of reliance on third-party goods and services; the risk of failure in information technology, data protection or cybercrime; the risk of failure of critical processes; any expected gains from productivity initiatives are uncertain; the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce; the risk of failure to adhere to applicable laws, rules and regulations; the risk of the safety and efficacy of marketed medicines being questioned; the risk of adverse outcome of litigation and/or governmental investigations; the risk of failure to adhere to increasingly stringent anti-bribery and anti-corruption legislation; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of failure in financial control or the occurrence of fraud; the risk of unexpected deterioration in the Group's financial position; and the impact that the COVID-19 global pandemic may have or continue to have on these risks, on the Group's ability to continue to mitigate these risks, and on the Group's operations, financial results or financial condition. Nothing in this document, or any related presentation/webcast, should be construed as a profit forecast.




Sustainability at AstraZeneca



Pam Cheng

EXECUTIVE VICE PRESIDENT, GLOBAL
OPERATIONS, INFORMATION TECHNOLOGY
AND CHIEF SUSTAINABILITY OFFICER



Sustainability Governance at AstraZeneca

Board of Directors – Delegated Committees

Board Audit Committee



Philip Broadley

Senior Independent Non-Executive Director of the Board,
Chair of the Audit Committee



Sheri McCoy

Non-Executive Director of the Board



Deborah DiSanzo

Non-Executive Director of the Board



Anna Manz

Non-Executive Director of the Board

Sustainability Committee



Nazneen Rahman

Non-Executive Director of the Board,
Chair of the Sustainability Committee



Sheri McCoy

Non-Executive Director of the Board



Marcus Wallenberg

Non-Executive Director of the Board



Andreas Rummelt

Non-Executive Director of the Board

Remuneration Committee



Sheri McCoy

Non-Executive Director of the Board,
Chair of the Remuneration Committee



Nazneen Rahman

Non-Executive Director of the Board



Philip Broadley

Senior Independent Non-Executive Director of the Board

Senior Executive Team (SET)



Pascal Soriot

Executive Director and Chief Executive Officer



Pam Cheng

Executive Vice President, Global Operations,
Information Technology and Chief Sustainability Officer



Jeff Pott

Chief Human Resources Officer, Chief Compliance Officer
and General Counsel

Sustainability Steering Committee

Sustainability

Compliance

Procurement

Communications

Legal

Finance

Human Resources

Supply Chain

Health Equity



2023 Sustainability highlights

Progress on our overall strategy includes:

15

public and private sector organisations convened by AstraZeneca CEO through the SMI to accelerate transition to net-zero health systems

87%

of employee survey respondents say that they understand their contributions to our sustainability priorities

25/27

of sustainability targets in Sustainability Data Annex are **“on plan”**

Access to Healthcare

127,384

healthcare workers and others trained¹ (cumulative)

By 2025: 170,000

>66.4m

people reached through Access to Healthcare programmes (cumulative)¹

By 2025: 50m

>13.6m

people reached through our patient assistance programmes (cumulative)

Environmental Protection

67.6%

reduction in Scope 1 and Scope 2 greenhouse gas emissions

By 2026: 98% from 2015 base year

19.5%

reduction in our water use

By 2025: 20% below 2015 baseline

13.2%

reduction in our waste

By 2025: 10% below 2015 baseline

Ethics and Transparency

50.1%

senior middle management roles held by women

By 2025: reach gender equality in management positions

11 countries

with supplier diversity programmes

By 2025: 10 new countries outside of the US

83%

of employee survey respondents feel we have a “speak up” culture





Access to Healthcare

Securing a future of access to affordable, sustainable, and innovative healthcare

Our ambition:

to promote prevention, increase access to life-saving treatments and strengthen global healthcare resilience and sustainability

Our focus:



Innovating



Partnering



Transforming

Progress in 2023

		TARGETS:
66.4m	People reached ¹	50m by 2025
127.3k	Healthcare workers trained ¹	170k by 2025

Access to Healthcare programmes include:



Metric "ON PLAN" Metric ACHIEVED

Strategy update

Broadening beyond philanthropic programmes for new **HEALTH EQUITY** strategy

COMPREHENSIVE STRATEGY from science to delivery of care


Implementing **END-to-END SOLUTIONS** across entire value chain

Further detail on Health Equity strategy later in 2024



Access to Healthcare

Partnering to drive focused interventions and policy change



Partnership for Health System Sustainability and Resilience (PHSSR)



Committed to collaborating across **SECTORS and BORDERS**



Building more **SUSTAINABLE and RESILIENT** health systems

Co-founded by:



Access in Action: PHSSR impact case studies



European Union

Acting Early on NCDs launched at European Parliament

Focus:

- Data and analytics
- Prevention and early intervention
- Innovative technologies and solutions

Japan

Digital solutions developed a digital platform for collecting and sharing medical information

Platform supporting:

- Guideline-based therapeutic decisions
- Detection of patients at early stages of their diseases

Brazil

Primary and community-based care identifying financial mechanisms to:

- Strengthen primary care
- Improve community-based disease management services

Improving global health by building more sustainable and resilient health systems



Access to Healthcare – Clinical Trial Diversity

Committed to designing clinical trials with equity at the forefront

Focused on:



PATIENT CENTRICITY



DATA DRIVEN approach



SCIENCE-LED execution

Progress in 2023



PUBLICATION


including retrospective analysis of 246 clinical trials in the US



Launch of internal **CTD DASHBOARD**

MONITORING CTD in the US

real-time tracking of for all recruiting Phase III trials¹



Committed to:

Designing **INCLUSIVE TRIALS**

Optimising **RECRUITMENT** and **RETENTION** of UREs

Improving **TRIAL DIVERSITY**

8 1. Current real-time tracking of race and ethnicity for all recruiting Phase III trials sponsored by AstraZeneca with plans to expand to include age and sex in 2024.

CTD = clinical trial diversity; FDA = US Food and Drug Administration; URE = under-represented ethnicities.



Environmental Protection


Driving bold decarbonisation through Ambition Zero Carbon

Scope 1 & 2



		TARGETS:
68%	Reduce Scope 1 & 2 emissions vs. 2015	98% by 2026 ✓
35%	Transition to electric vehicles	100% by 2025 ¹ ✓
103%	Increase energy productivity vs. 2015	200% by 2025 ✓
95%	Increase renewable electricity consumption vs. 2015	100% from 2025 ✓

Total Revenue vs. Scope 1 & 2 emissions




Scope 3



		TARGETS:
60%	Of suppliers with science-based targets	2025¹ ✓
	Launch next-generation near-zero GWP inhaler	By end of 2025 ✓

Scope 3: strategic emissions approach



✓ Metric "ON PLAN"

9 1. By 2025, 95% of our suppliers by spend covering purchased goods and services and capital goods, and 50% of our suppliers by spend covering upstream transportation and distribution and business travel, will have SBTs. tCO2e = tonnes of carbon dioxide equivalent; SBTi = Science Based Targets Initiative; GWP = Global Warming Potential.






Biodiversity at AstraZeneca

Integrating a circular economy approach across our value chain

Circular economy



Biodiversity

bringing nature more prominently into decision-making

By END of 2024:



Develop framework of biodiversity with **RISKS and DEPENDENCIES**



Developing **TARGETS and METRICS** according to SBTN

Supporting:



SCIENCE BASED TARGETS NETWORK
GLOBAL COMMONS ALLIANCE



AZ Forest

maximising the co-benefits of reforestation

TARGETS:

20m

Trees planted and maintained since 2020

200m 
by 2030

Reforestation designed to:

- Foster biodiversity
- Support sustainable livelihoods
- Build local climate resilience

 Metric "ON PLAN"





Ethics and Transparency

Ethical and transparent business, delivering positive impacts for patients and society

Our ambition:

ensuring ethical, open and inclusive behaviour across our organisation and value chain

Our focus:



Code of Ethics and Values



Value-based decision making



Visibility and transparency

Progress in 2023

WORKFORCE HEALTH and SAFETY

-59.6%

Reduce **total injury rate** vs. 2015

-75% by 2025



-52.5%

Reduce **collisions per million kilometres** driven vs. 2015

-55% by 2025



INCLUSION and DIVERSITY

TARGETS:

10

Launch ex-US **supplier diversity programmes**

in 2023:



10 by 2025



50.1%

Maintain **gender equality** in management positions

50/50 by 2025



ETHICAL BUSINESS CULTURE



POSITIVE SOURCING

ambition to achieve 100% ethical spend in alliance with **ecovadis**



Commitment to **3R FRAMEWORK** regarding animals in research

Replacement | Reduction | Refinement



Metric "ON PLAN"



Metric ACHIEVED





Ethics and Transparency

Cybersecurity, data protection and working ethically with AI

Data protection

Protecting enterprise cybersecurity via:


- 1 TRUST BY DESIGN**
- 2 CYBER AWARENESS TRAINING**
- 3 AI POWERED DEFENSES**

Supported by dedicated RESOURCES



24/7 INTERNAL and EXTERNAL
global cyber operations team

Use of AI in healthcare




2023 WHITE PAPER: regulations on AI in healthcare

Sustainable AI to Drive Global Health

A white paper summarizing opportunities of data and Artificial Intelligence in healthcare within the European Union and beyond

September 2023



Sustainability Reporting

Preparing for an evolving regulatory landscape

Regulatory updates



EU Corporate Sustainability Reporting Directive (**CSRD**)



European Sustainability Reporting Standards (**ESRS**)



EU Taxonomy



SASB Standards
published December 2023



IFRS Sustainability Disclosure Standards
expected adoption in 2024



SEC Climate Change Rule Amendment
expected April 2024



Already in effect



STANDARDS and FRAMEWORKS

- Actively monitoring changing landscape
- Participating in networks to develop emerging reporting practices



GAP ASSESSMENT

- Evaluating external reporting standards
- Aligning current disclosures



DOUBLE MATERIALITY

- In progress
- Informing future strategy
- Complying with regulations



- Leveraging technology to improve data capture
- Building a Sustainability platform to automate processes

Work ongoing to prepare for upcoming changes



Q&A Session

with Sustainability Leadership Team



Pam Cheng

EXECUTIVE VICE PRESIDENT, GLOBAL OPERATIONS, INFORMATION TECHNOLOGY AND CHIEF SUSTAINABILITY OFFICER



Stefan Weber

VICE PRESIDENT POLICY, PATIENT ADVOCACY AND HEALTH EQUITY



Juliette White

VICE PRESIDENT, GLOBAL SHE AND OPERATIONS SUSTAINABILITY



Beth Hamilton

VICE PRESIDENT GLOBAL MARKET ACCESS & PRICING, ONCOLOGY



David Ennis

HEAD OF ENVIRONMENTAL PROTECTION



Elena Tricca

VICE PRESIDENT GLOBAL MARKET ACCESS & PRICING, BIOPHARMACEUTICALS



Heather Stewart

VICE PRESIDENT, ETHICS AND TRANSPARENCY



Use of AstraZeneca slides from conference calls and webcasts

The AstraZeneca webcast, conference call and presentation slides (together the 'AstraZeneca materials') are for your personal, non-commercial use only. You may not copy, reproduce, republish, post, broadcast, transmit, make available to the public, sell or otherwise reuse or commercialise the AstraZeneca materials in any way. You may not edit, alter, adapt or add to the AstraZeneca materials in any way, nor combine the AstraZeneca materials with any other material. You may not download or use the AstraZeneca materials for the purpose of promoting, advertising, endorsing or implying any connection between you (or any third party) and us, our agents or employees, or any contributors to the AstraZeneca materials. You may not use the AstraZeneca materials in any way that could bring our name or that of any Affiliate into disrepute or otherwise cause any loss or damage to us or any Affiliate. AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA. Telephone + 44 20 3749 5000, www.astrazeneca.com

